Literature DB >> 15961220

Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters.

Yan J Song1, Chang F Qu, Syed M A Rizvi, Yong Li, G Robertson, Chand Raja, Alfred Morgenstern, Christos Apostolidis, Alan C Perkins, Barry J Allen.   

Abstract

The vectors PAI2, C595 and Herceptin target the membrane-bound uPA, MUC1 and HER2 antigens expressed by cancer cells, respectively. The expression of these receptors was tested in the ovarian cancer cell line OVCAR-3; MUC-1 was strongly expressed (3+), uPA moderately expressed (2+), but HER2 was negative (-). The alpha-emitting radionuclide Bismuth-213 was chelated with these targeting vectors to form alpha conjugates (ACs), the cytotoxicity of which were tested with OVCAR-3 cells. The PAI2 and C595 ACs are highly cytotoxic to the ovarian monolayer cancer cells and cell clusters in a concentration-dependent fashion and cause morphological changes of treated cancer cells, inducing apoptosis. These ACs are potential candidates for the control of ovarian cancer at the minimum residual disease (MRD) stage.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15961220     DOI: 10.1016/j.canlet.2005.03.060

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  11 in total

Review 1.  An overview of targeted alpha therapy.

Authors:  Young-Seung Kim; Martin W Brechbiel
Journal:  Tumour Biol       Date:  2011-12-06

2.  Biological response to nonuniform distributions of (210)Po in multicellular clusters.

Authors:  Prasad V S V Neti; Roger W Howell
Journal:  Radiat Res       Date:  2007-09       Impact factor: 2.841

3.  Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.

Authors:  Damian J Green; Mazyar Shadman; Jon C Jones; Shani L Frayo; Aimee L Kenoyer; Mark D Hylarides; Donald K Hamlin; D Scott Wilbur; Ethan R Balkan; Yukang Lin; Brian W Miller; Sofia H L Frost; Ajay K Gopal; Johnnie J Orozco; Theodore A Gooley; Kelly L Laird; Brian G Till; Tom Bäck; Brenda M Sandmaier; John M Pagel; Oliver W Press
Journal:  Blood       Date:  2015-01-27       Impact factor: 22.113

4.  The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model.

Authors:  Shyril O'Steen; Melissa L Comstock; Johnnie J Orozco; Donald K Hamlin; D Scott Wilbur; Jon C Jones; Aimee Kenoyer; Margaret E Nartea; Yukang Lin; Brian W Miller; Theodore A Gooley; Sherilyn A Tuazon; Brian G Till; Ajay K Gopal; Brenda M Sandmaier; Oliver W Press; Damian J Green
Journal:  Blood       Date:  2019-10-10       Impact factor: 22.113

5.  Astatine Radiopharmaceuticals: Prospects and Problems.

Authors:  Ganesan Vaidyanathan; Michael R Zalutsky
Journal:  Curr Radiopharm       Date:  2008-09-01

6.  Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.

Authors:  Sebastian Knör; Sumito Sato; Timo Huber; Alfred Morgenstern; Frank Bruchertseifer; Manfred Schmitt; Horst Kessler; Reingard Senekowitsch-Schmidtke; Viktor Magdolen; Christof Seidl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-22       Impact factor: 9.236

7.  Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.

Authors:  Li Wang; Hongmin Chen; Mohammad H Pourgholami; Julia Beretov; Jingli Hao; Hongtu Chao; Alan C Perkins; John H Kearsley; Yong Li
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

Review 8.  Targeted alpha anticancer therapies: update and future prospects.

Authors:  Barry J Allen; Chen-Yu Huang; Raymond A Clarke
Journal:  Biologics       Date:  2014-11-10

9.  Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression.

Authors:  H Chen; J Hao; L Wang; Y Li
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

10.  The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity.

Authors:  Blake J Cochran; Lakshitha P Gunawardhana; Kara L Vine; Jodi A Lee; Sergei Lobov; Marie Ranson
Journal:  BMC Biotechnol       Date:  2009-05-14       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.